The People with Asperger syndrome and anxiety disorders (PAsSA) trial: a pilot multicentre, single-blind randomised trial of group cognitive-behavioural therapy.

BACKGROUND: There is a growing interest in using cognitive-behavioural therapy (CBT) with people who have Asperger syndrome and comorbid mental health problems. AIMS: To examine whether modified group CBT for clinically significant anxiety in an Asperger syndrome population is feasible and likely to be efficacious. METHOD: Using a randomised assessor-blind trial, 52 individuals with Asperger syndrome were randomised into a treatment arm or a waiting-list control arm. After 24 weeks, those in the waiting-list control arm received treatment, while those initially randomised to treatment were followed up for 24 weeks. RESULTS: The conversion rate for this trial was high (1.6:1), while attrition was 13%. After 24 weeks, there was no significant difference between those randomised to the treatment arm compared with those randomised to the waiting-list control arm on the primary outcome measure, the Hamilton Rating Scale for Anxiety. CONCLUSIONS: Trials of psychological therapies with this population are feasible. Larger definitive trials are now needed. DECLARATION OF INTEREST: None. COPYRIGHT AND USAGE: © The Royal College of Psychiatrists 2016. This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY) licence.This research was supported by a grant from the National Institute for Health Research, Research for Patient Benefit funding stream (Grant reference: PB-PG-1208-18024), trial registration: ISRCTN 30265294 (DOI: 10.1186/ISRCTN30265294), UKCRN 8370. P.E.L. is supported by a National Institute for Health Research Postdoctoral Fellowship (Grant Reference: NIHR-PDF-2011-04-040). This article presents independent research funded by the National Institute for Health Research (NIHR